Cencora, Inc. Discloses Walgreens Volume Shift; Reaffirms FY26 EPS Guidance

What Happened
Cencora, Inc. announced in an 8-K (filed Aug 12, 2026) that beginning July 1, 2026 certain Walgreens volume that had been serviced by Cencora outside the prime vendor agreement began moving outside the company. The company says this change was fully contemplated in its Aug 5, 2026 commentary on fourth-quarter expectations for the U.S. Healthcare Solutions segment. Cencora confirmed the prime vendor agreement with Walgreens remains unchanged and still represents the vast majority of its Walgreens business, and the company reaffirmed its previously issued fiscal 2026 adjusted diluted EPS guidance of $17.75 to $17.95.

Key Details

• The volume shift began on July 1, 2026 and concerns activity outside the existing prime vendor agreement.
• The prime vendor agreement with Walgreens is unchanged and constitutes the vast majority of Cencora’s Walgreens business.
• Cencora reaffirmed FY2026 adjusted diluted EPS guidance: $17.75 to $17.95.
• The item was disclosed under Regulation FD and references prior commentary dated Aug 5, 2026.

Why It Matters
For investors, the filing signals a change in how some Walgreens business is handled but does not indicate a change to the core prime vendor relationship that drives most Walgreens revenue with Cencora. Reaffirming the FY26 adjusted diluted EPS range suggests management does not expect the disclosed shift to materially alter the company’s earnings outlook for the year. The filing also includes the standard forward-looking statements caution noting risks and that projections may change.